Endo’s lawyers and the attorneys representing the states, cities and counties suing the drugmaker have not discussed specific settlement figures. However, there has been discourse regarding how the company will change its marketing practices, three unnamed sources familiar with the matter told Bloomberg.
Endo aims to settle the existing lawsuits by 2018. A settlement would help Endo dodge “a multibillion-dollar litigation threat” as the company works to reduce costs and trim its workforce to lessen its $8 billion debt load, according to the report..
“Were Endo able to negotiate a separate settlement agreement, it likely suggests a smaller settlement amount than most feared, resolved at an earlier date,” Mike Holland, a senior credit analyst at Bloomberg Intelligence, told Bloomberg. “Right or wrong, that positive price movement today reflects a potentially diminished risk.”
More articles on opioids:
Son of Purdue Pharma owner wins patent for opioid dependence treatment
BCBS of Tennessee to drop OxyContin coverage in 2019
#NOpioid ad campaign promotes medical marijuana for pain management
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.